o(6)-benzylguanine has been researched along with Glial Cell Tumors in 21 studies
O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity
| Excerpt | Relevance | Reference |
|---|---|---|
| "To estimate the sustained (≥8 weeks) objective response rate in pediatric patients with recurrent or progressive high-grade gliomas (HGG, Stratum A) or brainstem gliomas (BSG, Stratum B) treated with the combination of O6-benzylguanine (O6BG) and temozolomide(®) (TMZ)." | 9.16 | A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. ( Balis, FM; Berg, SL; Boyett, JM; Geyer, JR; Goldman, S; Gururangan, S; Kun, LE; McLendon, RE; Minturn, JE; Packer, RJ; Pollack, IF; Poussaint, TY; Wallace, D; Warren, KE, 2012) |
| "This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide." | 9.14 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)." | 9.14 | Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas." | 9.10 | Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. ( Bigner, DD; Colvin, OM; Delaney, S; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Haglund, MM; Herndon, JE; Kaplan, R; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Tourt-Uhlig, S, 2002) |
| "Temozolomide (TMZ, 3,4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-as-tetrazine-8-carboxamide) is a new alkylating agent with promising antitumour efficacy for malignant gliomas." | 7.72 | Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. ( Germano, IM; Ito, H; Kanzawa, T; Kondo, S; Kondo, Y; Kyo, S, 2003) |
| "Temozolomide (TMZ) is a newly approved alkylating agent for the treatment of malignant gliomas." | 7.71 | Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. ( Berman, E; Gallo, JM; Ma, J; Murphy, M; O'Dwyer, PJ; Reed, K, 2002) |
| "Temozolomide (TMZ) is a DNA alkylating agent currently used as adjuvant treatment for anaplastic astrocytomas." | 5.32 | Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. ( Bedwell, J; Germano, IM; Kanzawa, T; Kondo, S; Kondo, Y, 2003) |
| "To estimate the sustained (≥8 weeks) objective response rate in pediatric patients with recurrent or progressive high-grade gliomas (HGG, Stratum A) or brainstem gliomas (BSG, Stratum B) treated with the combination of O6-benzylguanine (O6BG) and temozolomide(®) (TMZ)." | 5.16 | A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. ( Balis, FM; Berg, SL; Boyett, JM; Geyer, JR; Goldman, S; Gururangan, S; Kun, LE; McLendon, RE; Minturn, JE; Packer, RJ; Pollack, IF; Poussaint, TY; Wallace, D; Warren, KE, 2012) |
| "This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide." | 5.14 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)." | 5.14 | Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas." | 5.10 | Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. ( Bigner, DD; Colvin, OM; Delaney, S; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Haglund, MM; Herndon, JE; Kaplan, R; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Tourt-Uhlig, S, 2002) |
| "DNA alkylating agents including temozolomide (TMZ) and 1,3-bis[2-chloroethyl]-1-nitroso-urea (BCNU) are the most common form of chemotherapy in the treatment of gliomas." | 3.74 | The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. ( Chen, CC; D'Andrea, A; Taniguchi, T, 2007) |
| "Temozolomide (TMZ)-induced O6-methylguanine (MG) DNA lesions, if not removed by MG-DNA methyltransferase (MGMT), mispair with thymine, trigger rounds of futile mismatch repair (MMR), and in glioma cells lead to prolonged G2-M arrest and ultimately cell death." | 3.72 | Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. ( Berger, MS; Erickson, LC; Hirose, Y; Kreklau, EL; Pieper, RO, 2003) |
| "Temozolomide (TMZ, 3,4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-as-tetrazine-8-carboxamide) is a new alkylating agent with promising antitumour efficacy for malignant gliomas." | 3.72 | Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. ( Germano, IM; Ito, H; Kanzawa, T; Kondo, S; Kondo, Y; Kyo, S, 2003) |
| "Temozolomide (TMZ) is a newly approved alkylating agent for the treatment of malignant gliomas." | 3.71 | Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. ( Berman, E; Gallo, JM; Ma, J; Murphy, M; O'Dwyer, PJ; Reed, K, 2002) |
| "Temozolomide (TMZ) is a DNA alkylating agent currently used as adjuvant treatment for anaplastic astrocytomas." | 1.32 | Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. ( Bedwell, J; Germano, IM; Kanzawa, T; Kondo, S; Kondo, Y, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 14 (66.67) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, G | 1 |
| Zhao, L | 1 |
| Fan, T | 1 |
| Li, S | 1 |
| Zhong, R | 1 |
| Liu, C | 1 |
| Yao, S | 1 |
| Li, X | 1 |
| Wang, F | 1 |
| Jiang, Y | 1 |
| Quinn, JA | 5 |
| Jiang, SX | 3 |
| Reardon, DA | 5 |
| Desjardins, A | 4 |
| Vredenburgh, JJ | 3 |
| Rich, JN | 3 |
| Gururangan, S | 6 |
| Friedman, AH | 4 |
| Bigner, DD | 4 |
| Sampson, JH | 5 |
| McLendon, RE | 6 |
| Herndon, JE | 5 |
| Walker, A | 2 |
| Friedman, HS | 5 |
| Warren, KE | 1 |
| Geyer, JR | 1 |
| Poussaint, TY | 1 |
| Wallace, D | 1 |
| Balis, FM | 1 |
| Berg, SL | 1 |
| Packer, RJ | 1 |
| Goldman, S | 1 |
| Minturn, JE | 1 |
| Pollack, IF | 1 |
| Boyett, JM | 1 |
| Kun, LE | 1 |
| Hirose, Y | 1 |
| Kreklau, EL | 3 |
| Erickson, LC | 3 |
| Berger, MS | 1 |
| Pieper, RO | 1 |
| Kanzawa, T | 2 |
| Germano, IM | 2 |
| Kondo, Y | 2 |
| Ito, H | 1 |
| Kyo, S | 1 |
| Kondo, S | 2 |
| Bedwell, J | 1 |
| Pollok, KE | 1 |
| Bailey, BJ | 1 |
| Liu, N | 1 |
| Hartwell, JR | 1 |
| Williams, DA | 2 |
| Weingart, J | 3 |
| Brem, H | 2 |
| Dolan, ME | 5 |
| Delaney, SM | 2 |
| Vredenburgh, J | 1 |
| Rich, J | 1 |
| Pegg, AE | 4 |
| Moschel, RC | 4 |
| Birch, R | 1 |
| Provenzale, JM | 2 |
| Dancey, JE | 1 |
| Maxwell, J | 1 |
| Tourt-Uhlig, S | 2 |
| Chen, CC | 1 |
| Taniguchi, T | 1 |
| D'Andrea, A | 1 |
| Grossman, SA | 1 |
| Carson, KA | 1 |
| Fisher, JD | 1 |
| Rosenblum, ML | 1 |
| Olivi, A | 1 |
| Judy, K | 1 |
| Tatter, SB | 1 |
| Mineura, K | 2 |
| Izumi, I | 1 |
| Watanabe, K | 1 |
| Kowada, M | 2 |
| Kohda, K | 2 |
| Ikenaga, M | 1 |
| Fukuchi, M | 1 |
| Terashima, I | 1 |
| Kurpad, C | 1 |
| Rhines, LD | 1 |
| Sampath, P | 1 |
| Tyler, BM | 1 |
| Kokkinakis, DM | 1 |
| Bocangel, DB | 1 |
| Schold, SC | 1 |
| Ma, J | 1 |
| Murphy, M | 1 |
| O'Dwyer, PJ | 1 |
| Berman, E | 1 |
| Reed, K | 1 |
| Gallo, JM | 1 |
| Pluda, J | 1 |
| Delaney, S | 1 |
| Kaplan, R | 1 |
| Colvin, OM | 1 |
| Haglund, MM | 1 |
| Stine, L | 1 |
| Mitchell, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Newly Diagnosed (Part 1) or Recurrent/Progressive (Parts 1 and 2) Cerebral Anaplastic Gliomas[NCT00006474] | Phase 1 | 0 participants | Interventional | 2001-03-31 | Completed | ||
| Phase I GLIADEL and Continuous Infusion of Intravenous O6-Benzylguanine Trial in Patients With Recurrent Malignant Glioma[NCT00004892] | Phase 1 | 0 participants | Interventional | 2000-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for o(6)-benzylguanine and Glial Cell Tumors
| Article | Year |
|---|---|
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resi | 2009 |
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2009 |
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Dacarbazine; DNA M | 2012 |
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease P | 2005 |
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carm | 2002 |
14 other studies available for o(6)-benzylguanine and Glial Cell Tumors
| Article | Year |
|---|---|
Investigations on the effect of O(6)-benzylguanine on the formation of dG-dC interstrand cross-links induced by chloroethylnitrosoureas in human glioma cells using stable isotope dilution high-performance liquid chromatography electrospray ionization tand
Topics: Alkylating Agents; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Deoxycytid | 2014 |
iRGD-mediated core-shell nanoparticles loading carmustine and O
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cell Line, Tum | 2017 |
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Survival; Colony | 2003 |
Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Division; Dacarbazine; DNA-Binding Proteins; Dos | 2003 |
Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repa | 2003 |
Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Carmustine; Glioma; Guanin | 2003 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
Potential of O6-methylguanine or O6-benzylguanine in the enhancement of chloroethylnitrosourea cytotoxicity on brain tumours.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Basal Ganglia; Brain Neoplasms; Cell Count; | 1994 |
[Study on potentiation of nitrosourea-cytotoxicity by DNA repair enzyme inhibitors in human brain tumor cells].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Drug Resis | 1997 |
Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Enzyme Inhibitors; Female; | 1999 |
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2000 |
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2001 |
Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; | 2002 |
Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.
Topics: Animals; Brain Neoplasms; Cricetinae; Dose-Response Relationship, Drug; Female; Glioma; Guanine; Hum | 1990 |